Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts

Nucleic Acids Research

Volumn 44, Issue 5, 2015, Pages 2093-2109

  Burel, Sebastien A ^a   Hart, Christopher E ^a   Cauntay, Patrick ^a   Hsiao, Jill ^a   Machemer, Todd ^a   Katz, Melanie ^a   Watt, Andy ^a   Bui, Huynh Hoa ^a   Younis, Husam ^a   Sabripour, Mahyar ^a   Freier, Susan M ^a   Hung, Gene ^a   Dan, Amy ^a   Prakash, T P ^a   Seth, Punit P ^a   Swayze, Eric E ^a   Bennett, C Frank ^a   Crooke, Stanley T ^a   Henry, Scott P ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; ASPARTATE AMINOTRANSFERASE; GAP ANTISENSE OLIGONUCLEOTIDE; LOCKED NUCLEIC ACID; MESSENGER RNA; MESSENGER RNA PRECURSOR; RIBONUCLEASE H; UNCLASSIFIED DRUG; OLIGONUCLEOTIDE; RIBONUCLEASE HI; RNA PRECURSOR; SMALL INTERFERING RNA; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; HYPERTRANSAMINASEMIA; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA DEGRADATION; RNA SEQUENCE; TRANSCRIPTOMICS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; MICROARRAY ANALYSIS;

ALANINE TRANSAMINASE; ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LIVER; MALE; MICE; MICE, INBRED BALB C; MICROARRAY ANALYSIS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H; RNA PRECURSORS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTOME;

EID: 84963812653     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv1210     Document Type: Article

References (58)

1. Yacyshyn, B., Bowen-Yacyshyn, M.B. and Shanahan, W. (1999) The clinical experience of antisense therapy to ICAM-1 in Crohn's disease. Curr. Opin. Mol. Ther., 1, 332-335.
2. Bennett, F.C. (2007) In: Crooke, S.T. (ed.), Antisense Drug Technologies, Second Edition. Taylor & Francis Group, LLC, Boca Raton, Vol. 2, pp. 273-303.
3. Monia, B.P., Lesnik, E.A., Gonzalez, C., Lima, W.F., McGee, D., Guinosso, C.J., Kawasaki, A.M., Cook, P.D. and Freier, S.M. (1993) Evaluation of 2' modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem., 268, 14514-14522.
4. Crooke, S.T., Vickers, T., Lima, W. and Wu, H. (2007) In: Crooke, S.T. (ed.), Antisense drug technology, principles, strategies and applications. Taylor & Francis Group, Boca Raton, FL, Vol. 2, pp. 5-46.
5. Bennett, C.F. and Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol., 50, 259-293.
6. Geary, R.S. (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug Metab. Toxicol., 5, 381-391.
7. Geary, R.S., Yu, R.Z., Watanabe, T., Henry, S.P., Hardee, G.E., Chappell, A., Matson, J., Sasmor, H., Cummins, L. and Levin, A.A. (2003) Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab. Dispos., 31, 1419-1428.
8. Yu, R.Z., Geary, R.S., Monteith, D.K., Matson, J., Truong, L., Fitchett, J. and Levin, A.A. (2004) Tissue disposition of a 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci., 93, 48-59.
9. Mullick, A.E., Fu, W., Graham, M.J., Lee, R.G., Witchell, D., Bell, T.A., Whipple, C.P. and Crooke, R.M. (2011) Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice. J. Lipid Res., 52, 885-896.
10. Merki, E., Graham, M.J., Mullick, A.E., Miller, E.R., Crooke, R.M., Pitas, R.E., Witztum, J.L. and Tsimikas, S. (2008) Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation, 118, 743-753.
11. Henry, S.P., Taylor, J., Midgley, L., Levin, A.A. and Kornbrust, D.J. (1997) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev., 7, 473-481.
12. Kastelein, J.J., Wedel, M.K., Baker, B.F., Su, J., Bradley, J.D., Yu, R.Z., Chuang, E., Graham, M.J. and Crooke, R.M. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation, 114, 1729-1735.
13. Gaudet, D., Brisson, D., Tremblay, K., Alexander, V.J., Singleton, W., Hughes, S.G., Geary, R.S., Baker, B.F., Graham, M.J., Crooke, R.M. et al. (2014) Targeting APOC3 in the familial chylomicronemia syndrome.N. Engl. J. Med., 371, 2200-2206.
14. Buller, H.R., Bethune, C., Bhanot, S., Gailani, D., Monia, B.P., Raskob, G.E., Segers, A., Verhamme, P., Weitz, J.I. and the, F.X.I.A.S.O.T.K.A.I. (2014) Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis.N. Engl. J. Med., 372, 232-240.
15. Wengel, J. (1999) Synthesis of 3'-C- and 4'-C-Branched Oligodeoxynucleotides and the Development of Locked Nucleic Acid (LNA). Acc. Chem. Res., 32, 301-310.
16. Burel, S.A., Han, S.R., Lee, H.S., Norris, D.A., Lee, B.S., Machemer, T., Park, S.Y., Zhou, T., He, G., Kim, Y. et al. (2013) Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther., 23, 213-227.
17. Seth, P.P., Siwkowski, A., Allerson, C.R., Vasquez, G., Lee, S., Prakash, T.P., Wancewicz, E.V., Witchell, D. and Swayze, E.E. (2009) Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem., 52, 10-13.
18. Swayze, E.E., Siwkowski, A.M., Wancewicz, E.V., Migawa, M.T., Wyrzykiewicz, T.K., Hung, G., Monia, B.P. and Bennett, C.F. (2007) Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res., 35, 687-700.
19. Bianchini, D., Omlin, A., Pezaro, C., Lorente, D., Ferraldeschi, R., Mukherji, D., Crespo, M., Figueiredo, I., Miranda, S., Riisnaes, R. et al. (2013) First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br. J. Cancer, 109, 2579-2586.
20. van Poelgeest, E.P., Swart, R.M., Betjes, M.G., Moerland, M., Weening, J.J., Tessier, Y., Hodges, M.R., Levin, A.A. and Burggraaf, J. (2013) Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am. J. Kidney Dis., 62, 796-800.
21. Raetz, E.A., Morrison, D., Romanos-Sirakis, E., Gaynon, P., Sposto, R., Bhojwani, D., Bostrom, B.C., Brown, P., Eckroth, E., Cassar, J. et al. (2014) A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J. Pediatr. Hematol. Oncol., 36, 458-463.
22. Kakiuchi-Kiyota, S., Koza-Taylor, P.H., Mantena, S.R., Nelms, L.F., Enayetallah, A.E., Hollingshead, B.D., Burdick, A.D., Reed, L.A., Warneke, J.A., Whiteley, L.O. et al. (2014) Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice. Toxicol. Sci., 138, 234-248.
23. Hagedorn, P.H., Yakimov, V., Ottosen, S., Kammler, S., Nielsen, N.F., Hog, A.M., Hedtjarn, M., Meldgaard, M., Moller, M.R., Orum, H. et al. (2013) Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther., 23, 302-310.
24. Seth, P.P., Jazayeri, A., Yu, J., Allerson, C.R., Bhat, B. and Swayze, E.E. (2012) Structure activity relationships of alpha-L-LNA modified phosphorothioate gapmer antisense oligonucleotides in animals. Mol. Ther. Nucleic Acids, 1, e47.
25. Stanton, R., Sciabola, S., Salatto, C., Weng, Y., Moshinsky, D., Little, J., Walters, E., Kreeger, J., DiMattia, D., Chen, T. et al. (2012) Chemical modification study of antisense gapmers. Nucleic Acid Ther., 22, 344-359.
26. Burdick, A.D., Sciabola, S., Mantena, S.R., Hollingshead, B.D., Stanton, R., Warneke, J.A., Zeng, M., Martsen, E., Medvedev, A., Makarov, S.S. et al. (2014) Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides. Nucleic Acids Res., 42, 4882-4891.
27. Dullea, R., Salatto, C., Sciabola, S., Chen, T., Dimattia, D., Gandhok, H., Kreeger, J., Weng, Y., Clark, T., Vage, C. et al. (2014) Study of CRTC2 pharmacology using antisense oligonuceotides. Nucleic Acid Ther., 24, 127-138.
28. Durig, J., Duhrsen, U., Klein-Hitpass, L., Worm, J., Hansen, J.B., Orum, H. and Wissenbach, M. (2011) The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia, 25, 638-647.
29. Koch, T.R.C., Hansen, H.F., Hansen, B., Straarup, E.M. and Kauppinen, S. (2008) In: Kurreck, J. (ed.), Therapeutic Oligonucleotides. RSC Biomolecular Sciences, pp. 103-141.
30. Westergaard, M.H.H.F., Thrue, C.A., Hansen, J.B., Kjaerulff, L.S., Straarup, E.M., Olsen, O., Dalby, L.W., Hildebrandt-Eriksen, L. and Kearney, P. (2006) SPC2968-A novel Hif-1{alpha} antagonist for treatment of clear cell renal cell carcinoma. J. Clin. Oncol., 24, 14581.
31. Tolcher, A.W., Patnaik, A., Papadopoulos, K.P., Agnew, J., Lokiec, F.M., Rezai, K., Kalambakas, S. and Buchbinder, A. (2011) Proceedings of the 102nd Annual Meeting of AACR, LB-409 (abstract), Orlando, Florida.
32. McKay, R.A., Miraglia, L.J., Cummins, L.L., Owens, S.R., Sasmor, H. and Dean, N.M. (1999) Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J. Biol. Chem., 274, 1715-1722.
33. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statistical Soc., 57, 289-300.
34. Jackson, A.L. and Linsley, P.S. (2004) Noise amidst the silence: off-target effects of siRNAs? Trends Genet., 20, 521-524.
35. Jackson, A.L., Bartz, S.R., Schelter, J., Kobayashi, S.V., Burchard, J., Mao, M., Li, B., Cavet, G. and Linsley, P.S. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol., 21, 635-637.
36. Burchard, J., Jackson, A.L., Malkov, V., Needham, R.H., Tan, Y., Bartz, S.R., Dai, H., Sachs, A.B. and Linsley, P.S. (2009) MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA, 15, 308-315.
37. Jackson, A.L. and Linsley, P.S. (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov., 9, 57-67.
38. Jackson, A.L., Burchard, J., Schelter, J., Chau, B.N., Cleary, M., Lim, L. and Linsley, P.S. (2006) Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA, 12, 1179-1187.
39. van Dongen, S., Abreu-Goodger, C. and Enright, A.J. (2008) Detecting microRNA binding and siRNA off-target effects from expression data. Nat. Methods, 5, 1023-1025.
40. Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P. and Burge, C.B. (2003) Prediction of mammalian microRNA targets. Cell, 115, 787-798.
41. Burel, S.A., Machemer, T., Ragone, F.L., Kato, H., Cauntay, P., Greenlee, S., Salim, A., Gaarde, W.A., Hung, G., Peralta, R. et al. (2012) Unique MOE-DNA chimeric oligonucleotide induces an atypical MDA5 dependent induction of type I interferon response. J. Pharmacol. Exp. Ther., 342, 150-162.
42. Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., Moffat, J., Brown, M., Fitzgerald, K.J. and Sabatini, D.M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell, 11, 859-871.
43. Asano, A., Tsubomatsu, K., Jung, C.G., Sasaki, N. and Agui, T. (2007) A deletion mutation of the protein tyrosine phosphatase kappa (Ptprk) gene is responsible for T-helper immunodeficiency (thid) in the LEC rat. Mamm. Genome, 18, 779-786.
44. Zhang, B.W., Zimmer, G., Chen, J., Ladd, D., Li, E., Alt, F.W., Wiederrecht, G., Cryan, J., O'Neill, E.A., Seidman, C.E. et al. (1996) T cell responses in calcineurin A alpha-deficient mice. J. Exp. Med., 183, 413-420.
45. Schmidt, V.A., Chiariello, C.S., Capilla, E., Miller, F. and Bahou, W.F. (2008) Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol. Cell. Biol., 28, 1489-1502.
46. Fischer, J., Koch, L., Emmerling, C., Vierkotten, J., Peters, T., Bruning, J.C. and Ruther, U. (2009) Inactivation of the Fto gene protects from obesity. Nature, 458, 894-898.
47. Park, D., Park, J., Park, S.G., Park, T. and Choi, S.S. (2008) Analysis of human disease genes in the context of gene essentiality. Genomics, 92, 414-418.
48. Pandey, S.K., Wheeler, T.M., Justice, S.L., Kim, A., Younis, H., Gattis, D., Jauvin, D., Puymirat, J., Swayze, E.E., Freier, S.M. et al. (2015) Identification and characterization of modified antisense oligonucleotides targeting dmpk in mice and nonhuman primates for the treatment of Myotonic Dystrophy type 1. J. Pharmacol. Exp. Ther., 355, 310-321.
49. Bhattacharjee, G., Revenko, A.S., Crosby, J.R., May, C., Gao, D., Zhao, C., Monia, B.P. and MacLeod, A.R. (2013) Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther., 23, 175-187.
50. Zhang, H., Lowenberg, E.C., Crosby, J.R., MacLeod, A.R., Zhao, C., Gao, D., Black, C., Revenko, A.S., Meijers, J.C., Stroes, E.S. et al. (2010) Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood, 116, 4684-4692.
51. Kierzek, E., Ciesielska, A., Pasternak, K., Mathews, D.H., Turner, D.H. and Kierzek, R. (2005) The influence of locked nucleic acid residues on the thermodynamic properties of 2'-O-methyl RNA/RNA heteroduplexes. Nucleic Acids Res., 33, 5082-5093.
52. You, Y., Moreira, B.G., Behlke, M.A. and Owczarzy, R. (2006) Design of LNA probes that improve mismatch discrimination. Nucleic Acids Res., 34, e60.
53. Straarup, E.M., Fisker, N., Hedtjarn, M., Lindholm, M.W., Rosenbohm, C., Aarup, V., Hansen, H.F., Orum, H., Hansen, J.B. and Koch, T. (2010) Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res., 38, 7100-7111.
54. Lima, W.F., Rose, J.B., Nichols, J.G., Wu, H., Migawa, M.T., Wyrzykiewicz, T.K., Vasquez, G., Swayze, E.E. and Crooke, S.T. (2007) The positional influence of the helical geometry of the heteroduplex substrate on human RNase H1 catalysis. Mol. Pharmacol., 71, 73-82.
55. Lima, W.F., Rose, J.B., Nichols, J.G., Wu, H., Migawa, M.T., Wyrzykiewicz, T.K., Siwkowski, A.M. and Crooke, S.T. (2007) Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol. Pharmacol., 71, 83-91.
56. Ostergaard, M.E., Southwell, A.L., Kordasiewicz, H., Watt, A.T., Skotte, N.H., Doty, C.N., Vaid, K., Villanueva, E.B., Swayze, E.E., Bennett, C.F. et al. (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res., 41, 9634-9650.
57. St Laurent, G., Shtokalo, D., Dong, B., Tackett, M.R., Fan, X., Lazorthes, S., Nicolas, E., Sang, N., Triche, T.J., McCaffrey, T.A. et al. (2013) VlincRNAs controlled by retroviral elements are a hallmark of pluripotency and cancer. Genome Biol., 14, R73.
58. Lindow, M., Vornlocher, H.P., Riley, D., Kornbrust, D.J., Burchard, J., Whiteley, L.O., Kamens, J., Thompson, J.D., Nochur, S., Younis, H. et al. (2012) Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat. Biotechnol., 30, 920-923.